Skip to main content

Table 2 Description of groups, gender, age and pain

From: Analysis of foot function in terms of different pharmacological treatments in a cohort of patients with rheumatoid arthritis: a longitudinal study

Ā 

Gender (women/men)

Age (2018)

VAS-general (2018)

VAS-foot (2018)

VAS-general (2023)

VAS-foot (2023)

MTX (n = 42)

80/20%

60.7 ± 13.03

4.6 ± 2.99

3.9 ± 3.07

5.62 ± 3.4

5.81 ± 3.1

Bio (n = 115)

85.71/14.29%

53.64 ± 11.11

5.71 ± 1.77

4.79 ± 2.46

5.18 ± 2.89

6 ± 2.4

MTX + Bio (n = 33)

67.65/32.35%

55.09 ± 12.37

4.53 ± 2.33

3.91 ± 2.75

5.59 ± 2.96

4.12 ± 2.49

Miscellaneous (n = 16)

77.78/22.22%

57.73 ± 8.85

5.8 ± 2.52

5.2 ± 3.03

6.43 ± 2.55

6.38 ± 2.50

  1. VAS: Visual Analogue Scales; MTX: Methotrexate: Bio: Biological